Basic research: An oral cyclic peptide drug to reverse kidney fibrosis?

Nature Reviews Nephrology

Volumn 8, Issue 4, 2012, Pages 193-

  Allison, Susan J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; CAPTOPRIL; CYCLOPEPTIDE; OSTEOGENIC PROTEIN 1; THR 123; UNCLASSIFIED DRUG; UREA;

APOPTOSIS; CELL INFILTRATION; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE DELETION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TUBULE EPITHELIUM; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RENAL PROTECTION; SHORT SURVEY; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; URETER OBSTRUCTION;

EID: 84859000598     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.26     Document Type: Short Survey

References (1)

1. Sugimoto, H. et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat. Med. doi:10.1038/nm.2629